JPRN-UMIN000005723已完成2 期
A study of efficacy of humanized anti-human IgE monoclonal antibody, omalizumab for the treatment of severe nonatopic asthma - Omalizumab for severe nonatopic asthma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with active cardiopulmonary diseases other than bronchial asthma or serious medical conditions (e.g. malignancy)
研究者
相似试验
已完成
不适用
Omalizumab in non-atopic asthmaAsthmaISRCTN90016959King's College London (UK)40
进行中（未招募）
1 期
The effect of Omalizumab on asthma controlAsthmaEUCTR2009-009154-25-GBKing's College London40
进行中（未招募）
1 期
Efficacité des immunoglobulines humaines normales (IGHN) dans les chocs toxiques (staphylococciques et streptococciques) : étude de faisabilité pédiatrique.MedDRA version: 18.0Level: PTClassification code 10044248Term: Toxic shock syndromeSystem Organ Class: 10021881 - Infections and infestationstoxic shock syndromeEUCTR2013-005509-29-FRHospices Civils de Lyon20
进行中（未招募）
1 期
STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE GERONIMO 19Patients aged 75 years and older with confirmed infection Covid19 and saturation SaO2= under 95% O2> 5 L / min disqualified from a care in the ICUMedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001768-27-FRCH Versailles39
进行中（未招募）
不适用
Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-blind, placebo-controlled studyIdiopathic DM and PM with insufficiently improved muscle strenght under conventional therapy(Glucocorticosteroids associated with immunosuppresors)EUCTR2005-002463-88-HUOrfagen44